RFA-DE-24-001: Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 24, 2023.
From the official notice on Grants.gov, last changed April 7, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIDCR, NCI
- Median yearly award$598,940
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DE-24-001 were run by National Institute of Dental and Craniofacial Research (NIDCR, 4 projects) and National Cancer Institute (NCI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DE-24-001 in the NIH Guide.
Key dates
| Posted | April 7, 2023 |
|---|---|
| Deadline | July 24, 2023 |
| Archived by Grants.gov | August 29, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).
Funded under RFA-DE-24-001 so far
NIH funded 5 projects under RFA-DE-24-001 in fiscal 2024 to 2026, at 5 institutions. The median yearly award was $598,940.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection | LSU Health Sciences Center | 2026 | $630,689 |
| Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models | Albert Einstein College of Medicine | 2026 | $570,112 |
| Characterize longitudinal events of oral high-risk human papillomavirus to alter risk for oropharyngeal cancer (CLEAR) | University of Maryland Baltimore | 2026 | $562,100 |
| Onco-immunologic factors contributing to OPSCC among people living with HIV | University of Alabama at Birmingham | 2026 | $697,916 |
| Earlier detection of HPV-related oropharynx cancer in people living with and without HIV | Johns Hopkins University | 2024 | $515,812 |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Oral Diseases and Disorders Research grants before
From fiscal 2021 to 2025, Oral Diseases and Disorders Research (93.121) awarded $1.9 billion across 2,263 grant awards, an average of $818,037 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 76 | $89.2 million |
| The Regents of the University of California, San Francisco | California | 84 | $80.5 million |
| University of Southern California | California | 41 | $78.6 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 58 | $55.9 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 66 | $51.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DE-24-001 still open?
No. It closed on July 24, 2023.
Who can apply for Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)?
Closed July 24, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DE-24-001?
NIH RePORTER lists 5 projects funded under RFA-DE-24-001 in fiscal 2024 to 2026, at 5 institutions. The most were at LSU Health Sciences Center, Albert Einstein College of Medicine, University of Maryland Baltimore.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)